Analyst Price Targets — VCYT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 4, 2026 12:03 pm | — | Morgan Stanley | $44.00 | $44.49 | TheFly | Veracyte price target lowered to $44 from $47 at Morgan Stanley |
| August 4, 2026 11:10 am | — | Stephens | $55.00 | $44.85 | TheFly | Veracyte price target lowered to $55 from $68 at Stephens |
| August 4, 2026 10:52 am | — | Piper Sandler | $54.00 | $44.85 | TheFly | Veracyte price target lowered to $54 from $66 at Piper Sandler |
| August 3, 2026 11:16 am | Kyle Mikson | Canaccord Genuity | $50.00 | $46.32 | TheFly | Veracyte price target lowered to $50 from $60 at Canaccord |
| July 31, 2026 9:08 am | Mike Matson | Needham | $69.00 | $59.78 | StreetInsider | Veracyte, Inc (VCYT) PT Raised to $69 at Needham |
| July 15, 2026 8:55 am | David Westenberg | Piper Sandler | $66.00 | $56.62 | TheFly | Veracyte initiated with an Overweight at Piper Sandler |
| July 14, 2026 10:56 am | — | Canaccord Genuity | $60.00 | $57.48 | TheFly | Veracyte price target raised to $60 from $42 at Canaccord |
| July 9, 2026 10:59 am | — | Morgan Stanley | $47.00 | $56.12 | TheFly | Veracyte price target raised to $47 from $37 at Morgan Stanley |
| June 29, 2026 11:01 am | Subbu Nambi | Guggenheim | $65.00 | $60.49 | TheFly | Veracyte price target raised to $65 from $45 at Guggenheim |
| June 1, 2026 3:06 pm | Mike Matson | Needham | $57.00 | $48.38 | StreetInsider | Veracyte, Inc (VCYT) PT Raised to $57 at Needham |
Latest News for VCYT
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 7:00 a.m. Eastern Time.
Canada Pension Plan Investment Board bought a new stake in Veracyte, Inc. (NASDAQ: VCYT) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 20,700 shares of the biotechnology company's stock, valued at approximately $1,216,000. Several other hedge funds and
Connor Clark and Lunn Investment Management Ltd. bought a new stake in Veracyte, Inc. (NASDAQ: VCYT) during the second quarter, according to its most recent disclosure with the SEC. The firm bought 26,948 shares of the biotechnology company's stock, valued at approximately $1,583,000. Other hedge funds and other institutional investors have also recently
Bamco Inc. NY purchased a new stake in Veracyte, Inc. (NASDAQ: VCYT) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 650,686 shares of the biotechnology company's stock, valued at approximately $38,215,000. Bamco Inc. NY owned approximately 0.81% of Veracyte at the
VCYT's Afirma and Decipher sales momentum supports growth, while competition, macro pressures and rising investments remain key concerns.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VCYT.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.